The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary of the enormous pricetag – shares are down -20% since the Japanese company first announced its interest in buying Shire last month.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.